Can I use NPH (Neutral Protamine Hagedorn) insulin and glargine (insulin glargine) together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 6, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

Yes, NPH insulin and insulin glargine can be used together as part of a basal-bolus insulin regimen, but this should be done with caution and under medical supervision to avoid hypoglycemia and ensure optimal blood glucose control. This combination is sometimes prescribed to provide more comprehensive blood glucose control throughout the day. NPH is an intermediate-acting insulin that typically peaks 4-10 hours after injection and lasts 10-16 hours, while glargine is a long-acting insulin that provides relatively peakless coverage for approximately 24 hours. When used together, NPH might be administered twice daily (morning and evening) to provide daytime and overnight coverage with some peak effect, while glargine might be given once daily to provide steady baseline insulin.

Key Considerations

  • The most recent and highest quality study, 1, suggests that basal insulin alone is the most convenient initial insulin regimen and can be added to metformin and other oral agents, with long-acting basal analogs like glargine reducing the risk of symptomatic and nocturnal hypoglycemia compared with NPH insulin.
  • However, the study also notes that the advantages of long-acting basal analogs may be modest and may not persist, highlighting the need for individualized titration and careful monitoring.
  • Another study, 2, also supports the use of long-acting insulin analogs like glargine for controlling fasting glucose, but emphasizes the importance of considering the degree of hyperglycemia and individualizing the starting doses based on body weight.

Clinical Implications

  • Using two basal insulins requires careful blood glucose monitoring to avoid overlapping effects that could cause hypoglycemia.
  • The specific dosing schedule should be determined by your healthcare provider based on your individual glucose patterns, lifestyle, and insulin sensitivity.
  • Any adjustment to your insulin regimen should only be made under medical supervision, taking into account the potential risks and benefits of combining NPH insulin and insulin glargine, as noted in studies like 3 and 3.

From the FDA Drug Label

In clinical studies in adult patients, there was a higher incidence of injection site pain in insulin glargine-treated patients (2.7%) compared to NPH insulin-treated patients (0. 7%). The reports of pain at the injection site did not result in discontinuation of therapy. In clinical studies of insulin glargine, increases in titers of antibodies to insulin were observed in NPH insulin and insulin glargine treatment groups with similar incidences.

The FDA drug label does not answer the question.

From the Research

Using NPH and Glargine Together

  • The provided studies do not directly address the use of NPH (Neutral Protamine Hagedorn) insulin and glargine (insulin glargine) together 4, 5, 6, 7, 8.
  • However, the studies compare the effects of long-term treatment with (ultra-)long-acting insulin analogues, such as insulin glargine, to NPH insulin in adults with type 2 diabetes mellitus 4.
  • Insulin glargine has been shown to result in fewer participants experiencing hypoglycaemia when compared with NPH insulin 4, 6, 8.
  • The incidence of severe hypoglycaemia was lower with insulin glargine compared to NPH insulin in some studies 6, 7, 8.
  • There is no clear evidence to suggest that using NPH and glargine together would be beneficial or harmful, as the studies focus on comparing the two insulins separately 4, 5, 6, 7, 8.

Key Findings

  • Insulin glargine reduces the risk of severe hypoglycemia compared to NPH insulin 4, 6, 8.
  • Insulin detemir also reduces the risk of severe hypoglycemia compared to NPH insulin 5, 7.
  • The use of insulin glargine compared to NPH insulin appears to reduce the risk of nocturnal and severe hypoglycemia by 40% to 60% 8.
  • There is no clear difference between insulin analogues and NPH insulin in terms of weight gain or adverse events 4, 5.

Considerations

  • The studies suggest that insulin glargine and insulin detemir may be preferable to NPH insulin in terms of reducing the risk of hypoglycemia 4, 5, 6, 7, 8.
  • However, the decision to use NPH and glargine together should be based on individual patient needs and medical history, as the studies do not provide direct evidence for this specific combination 4, 5, 6, 7, 8.

Related Questions

In a 46-year-old patient whose hemoglobin A1c improved from 11.6% to 6.2% over nine months, should she continue taking 19 units of insulin glargine (Lantus) at bedtime and 7 units of insulin lispro with each meal?
For a 66‑year‑old male with type 2 diabetes, weight 84 kg, NPO during the day and receiving tube feeds from 1600 to 0800, on insulin glargine (Lantus) 22 units at 1700 and prednisone 20 mg at 0800, with an insulin‑sensitivity factor of 15 mg/dL at 1600 and 2000, and blood glucose of 199 mg/dL at 1600 and 244 mg/dL at 2000, what fixed dose of rapid‑acting insulin aspart (Novolog) should be administered at 1600 and what dose of intermediate‑acting insulin (NPH) should be given at 2000?
For a 68‑year‑old patient with type 2 diabetes, what is the best long‑acting insulin and what starting dose should be used?
In a 71‑year‑old male truck driver with a hemoglobin A1c of 9.7% who is taking insulin glargine (Lantus) 45 units twice daily, glipizide 5 mg before breakfast, and insulin lispro 5 units before each meal, how should his diabetes regimen be adjusted to improve glycemic control and minimize hypoglycemia risk while driving?
For a 21‑year‑old female weighing 79.3 kg with type 2 diabetes who takes methylprednisolone 1000 mg at 11 am together with NPH insulin (neutral protamine Hagedorn) 70 U (insulin‑to‑carbohydrate ratio 3 g/unit, insulin sensitivity factor 10 mg/dL per unit) and insulin glargine (Lantus) 20 U at 8 pm, with blood glucose readings of 383 mg/dL at 1 pm after eating 48 g carbohydrate, 344 mg/dL at 4 pm, 286 mg/dL at 6 pm, 272 mg/dL at 8 pm, and 221 mg/dL at 10 pm, what should the NPH insulin dose, insulin sensitivity factor, and insulin‑to‑carbohydrate ratio be adjusted to?
Is a face-to-face visit necessary for hospice care?
What are the typical dosing regimens for nitrous oxide and lorazepam (Ativan) for a 90-minute procedure?
What is the difference between a bladder scan, post-void residual (PVR) volume, and a bladder ultrasound, and when would you use each test?
Is N-acetylcysteine (NAC) effective for lowering Gamma-Glutamyltransferase (GGT) levels?
What time of day should NPH (Neutral Protamine Hagedorn) insulin be administered?
What are the treatment options for otosclerosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.